Novo Nordisk Aktie 23159222 / DK0060534915
126.32
CHF
0.07
CHF
0.06%
18:00:00
BRX
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | Ausblick | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 92.37 |
| Novo Holdings A/S (Investment Company) | 5.86 |
| Government Pension Fund - Global (The) | 2.27 |
| American Funds EuroPacific Growth Fund | 2.05 |
| Vanguard Total International Stock Index Fund | 1.19 |
| American Funds New Perspective Fund | 1.06 |
| Fundsmith Equity Fund | 0.92 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Personal am Ende des Jahres | 43'202 | 43'258 | 45'323 | 47'792 |
| Umsatz pro Mitarbeiter in Mio. EUR | 2.59 | 2.82 | 2.80 | 2.95 |
Bilanz (in Mio. EUR) - Aktiva
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Summe Umlaufvermögen | 59'067 | 62'456 | 65'809 | 85'595 |
| Summe Anlagevermögen | 52'354 | 62'076 | 73'681 | 97'391 |
| Summe Aktiva | 110'769 | 125'612 | 144'922 | 194'508 |
Bilanz (in Mio. EUR) - Passiva
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 515 | 4'483 | 10'356 | 26'645 |
| Summe Fremdkapital | 58'930 | 68'019 | 81'597 | 123'762 |
| Summe Eigenkapital | 51'839 | 57'593 | 63'325 | 70'746 |
| Summe Passiva | 110'769 | 125'612 | 144'922 | 194'508 |
Adresse
| Novo Allé 1, 2880 Bagsværd | |
| URL | http://www.novonordisk.com |
Management
|
Andreas Fibig
Independent Director |
|
Camilla Sylvest
EVP-Commercial Strategy & Corporate Affairs |
|
Daniel Bohsen
Vice President & Head-Investor Relations |
|
Doug Langa
EVP & Head-North America Operations |
|
Elisabeth Dahl Christensen
Director |
|
Helge Lund
Chairman |
|
Henrik Ehlers Wulff
Executive VP & Head-Information Technology |
|
Henrik Poulsen
Director |
|
Irina Ivanischeva
Vice President & General Manager |
|
Jane Buus Laursen
Corporate Vice President |
|
Jeppe Fonager Christiansen
Vice Chairman |
|
Jill Branca Priselac
Vice President-R&D, Business Development |
|
John McDonald
Vice President-R&D, Business Development |
|
Karsten Munk Knudsen
Chief Financial Officer & Executive Vice President |
|
Kasim Kutay
Director |
|
Lars Fruergaard Jørgensen
President & Chief Executive Officer |
|
Laurence Debroux
Independent Director |
|
Liselotte Hyveled
Director |
|
Ludovic Helfgott
Executive Vice President & Head-Biopharm |
|
Marcus Schindler
Chief Scientific Officer & Executive VP-Research |
|
Martin Holst Lange
Executive Vice President & Head-Development |
|
Martin W. MacKay
Independent Director |
|
Maziar Mike Doustdar
Executive Vice President-International Operations |
|
Mette Bøjer Jensen
Director |
|
Monique Carter
Executive Vice President-People & Organization |
|
Peter Jens Lindholm Kurtzhals
Senior Vice President-Global Research |
|
Robin Evers
SVP-Medical Affairs, Regulatory & Safety |
|
Sergey Manelis
Commercial Director |
|
Stephen Gough
Global Chief Medical Officer |
|
Sylvie Louise Grégoire
Independent Director |
|
Thomas Rantzau
Director |
